Wrong incentives

Bain and Cinven’s 5.3 billion euro offer for the drugmaker collapsed despite a 49 percent premium. While the bidders may have a second go, the debacle is a lesson in how investment strategies that exploit misguided takeover rules can go terribly wrong.